Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) EBIAT (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBIAT for 13 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 493.02% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.9 million through Dec 2025, up 287.7% year-over-year, with the annual reading at $105.9 million for FY2025, 287.7% up from the prior year.
  • EBIAT for Q4 2025 was $61.0 million at Theravance Biopharma, up from $3.6 million in the prior quarter.
  • The five-year high for EBIAT was $61.0 million in Q4 2025, with the low at -$86.5 million in Q1 2021.
  • Average EBIAT over 5 years is -$16.9 million, with a median of -$14.9 million recorded in 2022.
  • The sharpest move saw EBIAT plummeted 82.46% in 2024, then surged 493.02% in 2025.
  • Over 5 years, EBIAT stood at -$32.0 million in 2021, then skyrocketed by 55.5% to -$14.3 million in 2022, then skyrocketed by 40.31% to -$8.5 million in 2023, then tumbled by 82.46% to -$15.5 million in 2024, then soared by 493.02% to $61.0 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $61.0 million, $3.6 million, and $54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.